Search: onr:"swepub:oai:gup.ub.gu.se/286856" >
Alzheimer's Disease...
Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease
-
Hendrix, S. B. (author)
-
Soininen, H. (author)
-
van Hees, A. M. J. (author)
-
show more...
-
Ellison, N. (author)
-
- Visser, P. J. (author)
- Karolinska Institutet
-
- Solomon, A. (author)
- Karolinska Institutet
-
Attali, A. (author)
-
- Blennow, Kaj, 1958 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
- Kivipelto, M. (author)
- Karolinska Institutet
-
Hartmann, T. (author)
-
show less...
-
(creator_code:org_t)
- 2019
- 2019
- English.
-
In: Jpad-Journal of Prevention of Alzheimers Disease. - : SERDI. - 2274-5807 .- 2426-0266. ; 6:4, s. 232-236
- Related links:
-
https://link.springe...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- As research evolves in prodromal AD, the need to validate sufficiently sensitive outcome measures, e.g. the Alzheimer's Disease Composite Score (ADCOMS) is clear. In the LipiDiDiet randomized trial in prodromal AD, cognitive decline in the study population was much less than expected in the timeframe studied. While the primary composite endpoint was insufficiently sensitive to detect a difference in the modified intention to treat population, the per-protocol population showed less decline in the active than the control group, indicating better treatment effects with regular product intake. These results were further strengthened by significant benefits on secondary endpoints of cognition and function, and brain atrophy. The present post-hoc analysis investigated whether ADCOMS could detect a difference between groups in the LipiDiDiet population (138 active, 140 control). The estimated mean change in ADCOMS from baseline (standard error) was 0.085 (0.018) in the active and 0.133 (0.018) in the control group; estimated mean treatment difference -0.048 (95% confidence intervals -0.090, -0.007; p=0.023), or 36% less decline in the active group. This suggests ADCOMS identified the cognitive and functional benefits observed previously, confirming the sensitivity of this composite measure.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- Alzheimer's disease
- prodromal
- cognitive function
- nutrients
- Souvenaid
- Fortasyn
- criteria
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hendrix, S. B.
-
Soininen, H.
-
van Hees, A. M. ...
-
Ellison, N.
-
Visser, P. J.
-
Solomon, A.
-
show more...
-
Attali, A.
-
Blennow, Kaj, 19 ...
-
Kivipelto, M.
-
Hartmann, T.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Jpad-Journal of ...
- By the university
-
University of Gothenburg
-
Karolinska Institutet